SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med. 1995; 333: 1052-1057.
  • 2
    Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975; 46: 219-234.
  • 3
    Juliusson G, Merup M. Cytogenetics in chronic lymphocytic leukemia. Semin Oncol. 1998; 25: 19-26.
  • 4
    Juliusson G, Oscier DG, Fitchett M, et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med. 1990; 323: 720-724.
  • 5
    Kröber A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002; 100: 1410-1416.
  • 6
    Döhner H, Stilgenbauer S, Döhner K, Bentz M, Lichter P. Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis. J Mol Med. 1999; 77: 266-281.
  • 7
    Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000; 343: 1910-1916.
  • 8
    Liu Y, Hermanson M, Grandér D, et al. 13q Deletions in lymphoid malignancies. Blood. 1995; 86: 1911-1915.
  • 9
    Liu Y, Grandér D, Söderhäll S, Juliusson G, Gahrton G, Einhorn S. Retinoblastoma gene deletions in B-cell lymphocytic leukemia. Genes Chromosomes Cancer. 1992; 4: 250-256.
  • 10
    Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletion and down-regulation of micro-RNA genes miR-15 and miR-16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002; 99: 15524-15529.
  • 11
    Rai K, Patel DV. Chronic lymphocytic leukemia. In: Hoffman R, Benz EJ, Shaffil SJ, et al, eds. Hematology: Basic Principles and Practice. 3rd ed. Philadelphia, PA: Churchill Livingstone; 2000: 1350-1363.
  • 12
    Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996; 87: 4990-4997.
  • 13
    Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981; 48: 198-206.
  • 14
    Montserrat E, Sanchez-Bisono J, Viñolas N, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukemia: analysis of its prognostic significance. Br J Haematol. 1986; 62: 567-574.
  • 15
    Di Giovanni S, Valentini G, Carducci P, Giallonardo P. Beta-2-microglobulin is a reliable tumor marker in chronic lymphocytic leukemia. Acta Haematol. 1989; 81: 181-185.
  • 16
    Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003; 348: 1764-1775.
  • 17
    Döhner H, Stilgenbauer S, James MR, et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood. 1997; 89: 2516-2522.
  • 18
    Döhner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood. 1995; 85: 1580-1589.
  • 19
    Bullinger L, Krautle C, Busch R, et al. Incidence and correlation of genomic aberrations with clinical and biological risk factors in B-CLL stage Binet-A within the CLL1 trial of the GCLLSG [abstract]. Blood. 2001; 98( suppl 1): 359a. Abstract 1512.
  • 20
    Stilgenbauer S, Ritgen M, Bullinger L, et al. Genomic aberrations in the CLL trial of the German CLL Study Group (GCLLSG): deletion 11q23 identifies patients with molecular disease persistence after autologous high dose therapy [abstract]. Blood. 2001; 98( suppl 1):Page. Abstract 3180.
  • 21
    Juliusson G, Oscier D, Gahrton G, et al. International Working Party on Chromosomes in CLL (IWCCLL). Cytogenetic findings and survival in B-cell chronic lymphocytic leukemia. Second IWCCLL compilation of data on 662 patients. Leuk Lymphoma. 1991; 5( suppl 1): 21-25.
  • 22
    Reddy KS. Chronic lymphocytic leukaemia profiled for prognosis using a fluorescence in situ hybridization panel. Br J Hematol. 2006; 132: 705-722.
  • 23
    Dewald G, Brockman S, Paternoster S, et al. Chromosome anomalies detected by interphase fluorescence in situ, hybridization; correlation with significant biological features on B-cell chronic lymphocytic leukaemia. Br J Haematol. 2003; 121: 287-295.
  • 24
    Fink S, Geyer S, Shanafelt, et al. Clinical significance of homozygous D13S319 deletion in b-cell chronic lymphocytic leukemia (B-CLL) [abstract]. Blood. 2004; 2799: 766a. Abstract 104.
  • 25
    Chena C, Avalos J, Bezares R, et al. Biallelic deletion 13q14.3 in patients with chronic lymphocytic leukemia: cytogenetic, FISH and clinical studies. Eur J Haematol. 2008; 81: 94-99.
  • 26
    Pfeifer D, Pantic M, Skatulla I, et al. Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays. Blood. 2007; 109: 1201-1210.
  • 27
    Ripollés L, Ortega M, Ortuño F, et al. Genetic abnormalities and clinical outcome in chronic lymphocytic leukemia. Cancer Genet Cytogenet. 2006; 171: 57-64.
  • 28
    Van Dyke DL, Shanafelt TD, Call TG, et al. A comprehensive evaluation of the prognostic significance of 13q deletions in patients with B-chronic lymphocytic leukaemia. Br J Haematol. 2009; 148: 544-550.
  • 29
    Hernández JA, Rodríguez AE, González M, et al. A high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia. Haematologica. 2009; 94: 364-371.